Priyadarsini R, Maheswari Y Nisha, Prabha M Lakshmi, Ramya J Ezhil
Department of Pharmacology, Tirunelveli Medical College and Hospital, Tirunelveli, Tamil Nadu, India.
J Family Med Prim Care. 2023 Dec;12(12):3222-3227. doi: 10.4103/jfmpc.jfmpc_905_23. Epub 2023 Dec 21.
The perception of generic drugs may vary significantly between government and private doctors because physicians in the private sector have more prescribing choices and flexibility. Hence, this study was undertaken to analyse the knowledge, attitude and perception (KAP) of government and private physicians on generic drugs.
This was a questionnaire-based cross-sectional study conducted among physicians working in public and private health sectors. The questionnaire had 25 closed-ended questions related to the KAP of generic medicine. The overall scores were categorised using Bloom's cut-off point. The Chi-square or Mann-Whitney U-test was used to compare the differences between the two groups.
About 80% of the participants in both groups agreed that generic medicines contain the same active ingredients as brand-name drugs, are less expensive and are available in the Indian market. Nearly 84% of government physicians and only 64% of private physicians believed that generic medicines are just as effective and secure as branded medicines ( - 0.003). The majority of physicians from both groups concurred that there is a lack of quality check in generic drug manufacturing, and they require more information about bioequivalence studies. In both categories, about 75% of participants preferred generic medications for their patients. However, in both groups, more than 50% of physicians were concerned about therapeutic failure and expressed reluctance to prescribe generic medications in life-threatening situations.
Knowledge and acceptance of generic drugs regarding efficacy, safety, bioequivalence and therapeutic failure are low among both government and private physicians.
政府医生和私立医生对仿制药的认知可能存在显著差异,因为私立部门的医生有更多的处方选择和灵活性。因此,本研究旨在分析政府医生和私立医生对仿制药的知识、态度和认知(KAP)。
这是一项基于问卷的横断面研究,对象是在公共和私立卫生部门工作的医生。问卷有25个与仿制药KAP相关的封闭式问题。总体得分使用布鲁姆临界点进行分类。采用卡方检验或曼-惠特尼U检验比较两组之间的差异。
两组中约80%的参与者一致认为,仿制药与品牌药含有相同的活性成分,价格更低,且在印度市场有销售。近84%的政府医生和仅64%的私立医生认为仿制药与品牌药一样有效和安全(P = - 0.003)。两组中的大多数医生都认为仿制药生产缺乏质量检查,他们需要更多关于生物等效性研究的信息。在这两类医生中,约75%的参与者更愿意为患者开仿制药。然而,在两组中,超过50%的医生担心治疗失败,并表示在危及生命的情况下不愿开仿制药。
政府医生和私立医生对仿制药在疗效、安全性、生物等效性和治疗失败方面的知识和接受度都很低。